|
Hayward, CA, May 15, 2006 -- Sepragen Corporation (OTC BB: SPGNA.PK),
a provider of patented technology and equipment for purification
needs in the biotech and nutraceutical industries, today announced
the addition of Biomedical Resources International, Inc. (BRI),
based in Northboro, MA, to its direct marketing channel. Under the
agreement signed between the two parties, BRI will represent Sepragen
in the North-eastern territory of MA, CT, NY, RI, NJ, PA, DE, MD,
VA and NC and sell, service and support Sepragen branded QuantaSep
Chromatography Instrument products and Superflo® Radial Flow
Columns, focused on the growing biotech market.
BRI is an established distributor of products for the bioprocess
markets representing several other companies with complementary
products in the above territory. BRI’s president, Alan Opper,
said of the equipment, “We are excited about being able to
offer Sepragen products to our customers. They are unique and well
differentiated and bring value to our bio-processing customers in
terms of scalability and throughput.”
Some of Sepragen products are also marketed by Pall Corporation
and sold under the Pall Life Sciences brand, as previously announced.
Sepragen is a provider of innovative bio-purification products that
enable biotech companies to develop and manufacture biopharmaceuticals
quickly and cost-effectively. Sepragen products are used by leading
biotech companies world-wide to manufacture over a dozen FDA approved
drugs.
<
Back
The statements in this release that relate to future events
or performance, statements about growth, future regulatory clearances, levels of sales and
market size and future manufacturing capacity and efficiencies are forward-looking
statements that involve risks and uncertainties, including risks associated with
uncertainties related to the development of markets for and commercial acceptance of the
company's products and services, the availability of components, competitors' product
introductions and other risks identified in the company's SEC filings. Actual results may
differ from those described in these forward-looking statements. Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak only as of the
date hereof.
|
